Rapport Therapeutics (NASDAQ:RAPP) was upgraded by analysts at
Wall Stre
Rapport Therapeutics (NASDAQ:RAPP) was downgraded by analysts at
Wall St
Rapport Therapeutics (NASDAQ:RAPP) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Assessing Rapport Therapeutics (RAPP) Valuation After Recent Share Price Strength [Yahoo! Finance]
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline